Navigation Links
ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union
Date:6/24/2011

EXTON, Pa., June 24, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a Pediatric Use Marketing Authorization (PUMA) for Buccolam® (midazolam, oromucosal solution), for treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years.  If approved by the European Commission, Buccolam would be the first product approved through the centralized PUMA procedure.

Buccolam is oral midazolam provided in a pre-measured, age-specific dose formulation for convenient buccal (i.e. via the cavity between the cheek and gum line) delivery. Buccal midazolam has been shown in four clinical studies to be either comparable or superior in both its effectiveness and speed of onset of action to the current standard treatment, rectally-administered diazepam, for terminating pediatric convulsive epileptic seizures.

"The potential approval of Buccolam would address a major challenge for physicians currently prescribing rectally-administered diazepam for acute seizures, namely that it can be difficult to use and may be socially unacceptable in the community," said Professor Ian Wong, Director of the Centre for Paediatric Pharmacy Research at the School of Pharmacy, University of London. "Midazolam is recommended for treating prolonged acute convulsive seizures according to published treatment guidelines in European countries, and the availability of Buccolam – an oromucosal formulation of midazolam – would be an important, convenient and welcomed alternative to treat seizures in pediatric and adolescent patients."

The CHMP is responsible for issuing the EMA's scientific evaluation and opinions on all Marketing Au
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
2. ViroPharma to Participate in the Jefferies 2011 Global Healthcare Conference
3. ViroPharma Launches Swell, an Original Documentary Chronicling the Lives of People Living with Hereditary Angioedema
4. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
5. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
6. ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor
7. ViroPharma to Participate In Three May Healthcare Investor Conferences
8. ViroPharma to Release 2011 First Quarter Financial Results On April 28, 2011
9. ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR)
10. ViroPharma Launches HAE and Me, A New Online Community to Unite People Living With Hereditary Angioedema
11. ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Hovione today announced that its API plant in ... pre-approval inspection by the US Food and Drug Administration (FDA). ... Safety Officer, Ms. Britanny Terhar , lasted 5 days ... concluded on the 25 th . The inspection confirmed the ... Good Manufacturing Practices (GMP) and no Form 483 observations were ...
(Date:7/31/2014)... VIENNA , July 31, 2014 ... in New York results of AFF008, ... Parkinson,s disease. PD01A is the first therapy against the protein ... The Michael J. Fox Foundation for Parkinson,s Research ... and presented at the press conference on the impact a ...
(Date:7/31/2014)... 2014 Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics ... a conference call on Thursday, August 14, 2014, at 4:30 ... ended June 30, 2014. Financial results will be issued in ... Chairman, President and CEO James LaFrance will host ... Date: Thursday, August 14, 2014 Time: 4:30 p.m. Eastern ...
Breaking Medicine Technology:Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2
... Life Technologies Corporation (NASDAQ: LIFE ) ... with GlaxoSmithKline Biologicals S.A. (GSK) to develop a diagnostic ... GSK candidate cancer immunotherapy. Specifically, Life will develop a ... candidate designed to identify patients likely to benefit from ...
... (Cayman) Inc. (NYSE: WX ), a leading ... operations in China and the United States, today announced ... quarter of 2011 after the New York Stock Exchange ... Friday morning, November 11, 2011 Shanghai time). The earnings ...
Cached Medicine Technology:Life Technologies Signs Agreement with GlaxoSmithKline Biologicals S.A., Seeking Expanded Use of Platform Technologies into Companion Diagnostics 2Life Technologies Signs Agreement with GlaxoSmithKline Biologicals S.A., Seeking Expanded Use of Platform Technologies into Companion Diagnostics 3Life Technologies Signs Agreement with GlaxoSmithKline Biologicals S.A., Seeking Expanded Use of Platform Technologies into Companion Diagnostics 4WuXi PharmaTech Schedules Third-Quarter 2011 Earnings Release 2
(Date:7/31/2014)... MI (PRWEB) July 31, 2014 The vineyards ... of the upcoming harvest. And, to celebrate, folks are gearing ... and Sunday, September 6 and 7, 2014 along the ... is an optional walk or run through the vineyards start-ing ... in Suttons Bay. A unique course between rows of grapevines ...
(Date:7/31/2014)... July 31, 2014 Cosmetic Town has ... patients and doctors. Doctors will be able to verify ... reviews , which guarantees their authenticity. This ... the site to receive information that has been verified ... validation system allows Cosmetic Town to filter out fake ...
(Date:7/31/2014)... 31, 2014 NEWwoodworks, fine woodworking group ... their brand presence with a website dedicated to highlighting ... NEWwoodworks has specialized in handcrafted cabinetry, furniture, stairs ... has earned a reputation for taking on the remarkable, ... They commonly craft with reclaimed wood, often using near ...
(Date:7/31/2014)... US Hair Restoration Founder, Dr. Parsa Mohebi, has recently ... Mohebi Hair Restoration. Since first opening in 2008, US ... and around the world, who traveled to one of its ... patients achieved the full benefits of a variety of hair ... Dr. Mohebi. They have come to understand how his ...
(Date:7/31/2014)... July 31, 2014 Daily Gossip indicates ... pain killers for this health problem. However, this is ... new program was created by Peter Bansby, who decided ... sufferers from all over the world find a unique ... people wish to view pros and cons from a ...
Breaking Medicine News(10 mins):Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers a Unique Vineyard Course for Walkers, Runners and Wine Tasters 2Health News:Cosmetic Town Improves Patient Experience Through Secure Verification of Patients and Doctors 2Health News:NEWwoodworks Fine Woodworking Group Launches New Website 2Health News:NEWwoodworks Fine Woodworking Group Launches New Website 3Health News:US Hair Restoration Becomes Parsa Mohebi Hair Restoration 2Health News:Neuropathy Miracle Review Reveals Peter Bansby's Unique Cure Method 2
... NEW YORK, July 1 Prostate cancer is the ... caught early, prostate cancer,has a 90% cure rate., ... and,Minimally Invasive Surgery, Department of Urology, at Mount Sinai ... to wait until there are,warning signs, because by then ...
... Meet Aggressive Hospital Opening Schedule; Eases Ongoing IT Development ... ... RIOJA, Spain, July 1 TIBCO Software Inc.,(Nasdaq: TIBX ) ... Rioja has deployed its real-time integration,infrastructure. The project at Servicio Riojano ...
... Growth In All Existing Markets -, LONG ... Bulletin Board: CHRX, CHRXU, CHRXW), a leading provider ... surpassed,67,000 beds served, a five percent increase over ... all five of its institutional facilities,including Long Beach, ...
... July 1 ETHICON, Inc., a Johnson &,Johnson ... offer from One Equity Partners to acquire the ... process to,prepare for the divestiture of the Professional ... process and receipt of the offer has decided ...
... Healthcare Underwriters Group Mutual of Ohio (HUOH), the only medical liability ... by Ohio physicians, announced today that it will make its first ... Board of Directors after the company achieved outstanding loss results for ... single paid loss. , ...
... support organization for families going through the natural ... is hosting its 31st national conference July 18-20 ... and grandparents, as well as professionals who provide ... include well-known speakers, more than 100 workshops covering ...
Cached Medicine News:Health News:With Prostate Cancer: Waiting for Symptoms Is Not an Option 2Health News:Rioja Hospital Uses TIBCO Software to Improve Customer Care and Streamline Operations 2Health News:Chem Rx Corporation Surpasses 67,000 Beds Served 2Health News:ETHICON Receives Offer from One Equity Partners to Purchase Professional Wound Care Business 2Health News:ETHICON Receives Offer from One Equity Partners to Purchase Professional Wound Care Business 3Health News:ETHICON Receives Offer from One Equity Partners to Purchase Professional Wound Care Business 4Health News: Great Doctors Produce Great Results (Healthcare Underwriters Group Mutual of Ohio Pays A Cash Dividend): -- Healthcare Underwriters Group Mutual of Ohio Pays Its First Cash Distribution to Its Insured Owners 2Health News:Families Mourning Children Travel to Nashville for July Compassionate Friends National Conference 2
Unmatched versatility for hemostasis wherever needed. Can be applied to suit your needs....
Portable, easy to align, automatic measurement, automatic fogging. Accurate and dependable readings. Infrared printer communication. Rechargeable battery. Integrates with the TRS-2100 and EPIC-2100 r...
... Tango ophthalmic laser system provides two lasers ... and a photodisruptor for posterior capsulotomy and ... Nd:YAG producing pulsed 532 nm light. The ... nm. The appropriate laser can be easily ...
Thin and smooth jaws, designed to enter trough 3 mm incision, cross action....
Medicine Products: